Biotech · Private company
Pharmacyclics LLC.
Track this companyFree. Adds Pharmacyclics LLC. to your Dealase workspace and tells you when its record changes.
Clinical trials2511 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- IbrutinibPhase 3 · Mantle-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Ibrutinib Oral CapsulePhase 3 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Mantle-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ibrutinibPhase 2 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 2 · Chronic Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- venetoclaxPhase 2 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaPHASE2 · ACTIVE_NOT_RECRUITING · started May 30, 2024ClinicalTrials.gov NCT05963074 · fetched Nov 12, 2026
- Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 24, 2021ClinicalTrials.gov NCT04450173 · fetched Nov 12, 2026
- Ibrutinib + Venetoclax in Untreated WMPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 9, 2020ClinicalTrials.gov NCT04273139 · fetched Nov 12, 2026
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 23, 2019ClinicalTrials.gov NCT04212013 · fetched Nov 12, 2026
- Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaPHASE1 · COMPLETED · started Aug 29, 2019ClinicalTrials.gov NCT03702725 · fetched Nov 12, 2026
- Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)PHASE1 · COMPLETED · started Jan 22, 2019ClinicalTrials.gov NCT03703167 · fetched Nov 12, 2026
- Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)PHASE1_PHASE2 · COMPLETED · started Nov 19, 2018ClinicalTrials.gov NCT03790332 · fetched Nov 12, 2026
- Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCPHASE2 · TERMINATED · started Oct 17, 2018ClinicalTrials.gov NCT03646461 · fetched Nov 12, 2026
- Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)PHASE2 · COMPLETED · started May 23, 2018ClinicalTrials.gov NCT03207555 · fetched Nov 12, 2026
- Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibPHASE1 · ACTIVE_NOT_RECRUITING · started May 1, 2018ClinicalTrials.gov NCT03422393 · fetched Nov 12, 2026
- A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 17, 2018ClinicalTrials.gov NCT03462719 · fetched Nov 12, 2026
- Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 20, 2018ClinicalTrials.gov NCT03198026 · fetched Nov 12, 2026
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromePHASE1 · COMPLETED · started Dec 1, 2017ClinicalTrials.gov NCT03359460 · fetched Nov 12, 2026
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 29, 2017ClinicalTrials.gov NCT03379428 · fetched Nov 12, 2026
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic LeukemiaPHASE2 · COMPLETED · started Jun 27, 2017ClinicalTrials.gov NCT02997761 · fetched Nov 12, 2026
- Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)PHASE3 · COMPLETED · started Jun 19, 2017ClinicalTrials.gov NCT03112174 · fetched Nov 12, 2026
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaPHASE3 · COMPLETED · started Jan 23, 2017ClinicalTrials.gov NCT02947347 · fetched Nov 12, 2026
- Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)PHASE2 · COMPLETED · started Sep 28, 2016ClinicalTrials.gov NCT02910583 · fetched Nov 12, 2026
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · COMPLETED · started Jan 12, 2016ClinicalTrials.gov NCT02518555 · fetched Nov 12, 2026
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.PHASE1_PHASE2 · COMPLETED · started Aug 26, 2015ClinicalTrials.gov NCT02315768 · fetched Nov 12, 2026
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)PHASE1_PHASE2 · COMPLETED · started Dec 8, 2014ClinicalTrials.gov NCT02315326 · fetched Nov 12, 2026
- A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 1, 2014ClinicalTrials.gov NCT02251548 · fetched Nov 12, 2026
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 26, 2014ClinicalTrials.gov NCT01479842 · fetched Nov 12, 2026
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 9, 2013ClinicalTrials.gov NCT01804686 · fetched Nov 12, 2026
- PCI-24781 in Combination With Doxorubicin to Treat SarcomaPHASE1_PHASE2 · COMPLETED · started Feb 1, 2009ClinicalTrials.gov NCT01027910 · fetched Nov 12, 2026